Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk

被引:229
作者
Mirams, Gary R. [1 ]
Cui, Yi [2 ]
Sher, Anna [1 ]
Fink, Martin [1 ]
Cooper, Jonathan [3 ]
Heath, Bronagh M. [4 ]
McMahon, Nick C. [2 ]
Gavaghan, David J. [3 ]
Noble, Denis [1 ]
机构
[1] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3PT, England
[2] GlaxoSmithKline, Safety Assessment, Safety Pharmacol, Ware SG12 0DP, Herts, England
[3] Univ Oxford, Comp Lab, Oxford OX1 3QD, England
[4] GlaxoSmithKline, Global Clin Safety & Pharmacovigilance, Uxbridge UB11 1BT, Middx, England
关键词
Computer modelling; Drug development; Pharmacology; Risk prediction; Torsade-de-pointes; QT INTERVAL PROLONGATION; TORSADE-DE-POINTES; DRUG; HERG; MODEL; PROARRHYTHMIA; DYNAMICS; CELLML; SAFETY;
D O I
10.1093/cvr/cvr044
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The level of inhibition of the human Ether-a-go-go-related gene (hERG) channel is one of the earliest preclinical markers used to predict the risk of a compound causing Torsade-de-Pointes (TdP) arrhythmias. While avoiding the use of drugs with maximum therapeutic concentrations within 30-fold of their hERG inhibitory concentration 50% (IC50) values has been suggested, there are drugs that are exceptions to this rule: hERG inhibitors that do not cause TdP, and drugs that can cause TdP but are not strong hERG inhibitors. In this study, we investigate whether a simulated evaluation of multi-channel effects could be used to improve this early prediction of TdP risk. Methods and results We collected multiple ion channel data (hERG, Na, L-type Ca) on 31 drugs associated with varied risks of TdP. To integrate the information on multi-channel block, we have performed simulations with a variety of mathematical models of cardiac cells (for rabbit, dog, and human ventricular myocyte models). Drug action is modelled using IC50 values, and therapeutic drug concentrations to calculate the proportion of blocked channels and the channel conductances are modified accordingly. Various pacing protocols are simulated, and classification analysis is performed to evaluate the predictive power of the models for TdP risk. We find that simulation of action potential duration prolongation, at therapeutic concentrations, provides improved prediction of the TdP risk associated with a compound, above that provided by existing markers. Conclusion The suggested calculations improve the reliability of early cardiac safety assessments, beyond those based solely on a hERG block effect.
引用
收藏
页码:53 / 61
页数:9
相关论文
共 33 条
  • [1] Bisset AF, 2002, BRIT MED J, V325, P967
  • [2] Multiscale modelling of drug-induced effects on cardiac electrophysiological activity
    Brennan, T.
    Fink, M.
    Rodriguez, B.
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 36 (01) : 62 - 77
  • [3] Sodium channel blockers identify risk for sudden death in patients with ST-Segment elevation and right bundle branch block but structurally normal hearts
    Brugada, R
    Brugada, J
    Antzelevitch, C
    Kirsch, GE
    Potenza, D
    Towbin, JA
    Brugada, P
    [J]. CIRCULATION, 2000, 101 (05) : 510 - 515
  • [4] A MOLECULAR-BASIS FOR CARDIAC-ARRHYTHMIA - HERG MUTATIONS CAUSE LONG QT SYNDROME
    CURRAN, ME
    SPLAWSKI, I
    TIMOTHY, KW
    VINCENT, GM
    GREEN, ED
    KEATING, MT
    [J]. CELL, 1995, 80 (05) : 795 - 803
  • [5] Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes
    Darpö, B
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2001, 3 (0K) : K70 - K80
  • [6] Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use E14 Guideline
    Darpo, B
    Nebout, T
    T Sager, P
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (05) : 498 - 507
  • [7] Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death
    De Bruin, ML
    Pettersson, M
    Meyboom, RHB
    Hoes, AW
    Leufkens, HGM
    [J]. EUROPEAN HEART JOURNAL, 2005, 26 (06) : 590 - 597
  • [8] Cardiovascular risks of atypical antipsychotic drug treatment
    Drici, Milou-Daniel
    Priori, Silvia
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (08) : 882 - 890
  • [9] CellML and associated tools and techniques
    Garny, Alan
    Nickerson, David P.
    Cooper, Jonathan
    dos Santos, Rodrigo Weber
    Miller, Andrew K.
    McKeever, Steve
    Nielsen, Poul M. F.
    Hunter, Peter J.
    [J]. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY A-MATHEMATICAL PHYSICAL AND ENGINEERING SCIENCES, 2008, 366 (1878): : 3017 - 3043
  • [10] Antihistamine drug withdrawn by manufacturer
    Gottlieb, S
    [J]. BRITISH MEDICAL JOURNAL, 1999, 319 (7201) : 7 - 7